The understanding and treatment of type 1 diabetes (T1D) is advancing with technological advances. The discovery of insulin in 1921 revolutionized diabetes treatment and paved the way for the development of insulin pumps (IP) continuous glucose monitors (CGMs) and artificial pancreas (AP) systems, which have significantly improved diabetes management. IP provides continuous insulin delivery, offering benefits, such as adaptability, precise dosing, and improved glycemic control. The CGMs enable real-time glucose monitoring, leading to enhanced glycemic management and reduced hypoglycemia risk. The AP systems combine CGM and IP technologies to automate insulin delivery, resulting in improved outcomes and potential dual hormone systems using insulin and glucagon. Despite the potential of these technologies, challenges exist in utilizing them in India, including cost, insurance coverage, availability, awareness, healthcare infrastructure, trained professionals, cultural barriers, and data management issues. However, ongoing research and advanced research utilizing cutting-edge technologies offer hope for new therapies and ultimately a cure for T1D.